Fireside Panel Discussion on Diabetes sector

RNS Number : 8671N

Arecor Therapeutics PLC

06 January 2026

Arecor Therapeutics plc
("Arecor" or the "Company")

Arecor and Sequel Med Tech virtual fireside panel discussion

Cambridge, UK, 6 January 2026: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases, and Sequel Med Tech LLC ("Sequel"), a company developing state-of-the-art insulin delivery technologies, will be hosting a virtual fireside panel discussion on the future of the treatment journey for people with diabetes and factors driving diabetes innovation, on Wednesday 7 January 2026 at 16:00 GMT / 11:00 ET / 08:00 PT.

At this event, no new material information will be disclosed.

To register for the event, please email [email protected] or [email protected].

-ENDS-

For more information, please contact:

Arecor Therapeutics plc Dr Sarah Howell, Chief Executive Officer David Ellam, Chief Financial Officer	+44 (0) 1223 426060 [email protected]

Singer Capital Markets Advisory LLP (NOMAD and Broker to Arecor Therapeutics)	+44 (0) 20 7496 3000
Phil Davies, Andrew Johnson, James Todd

Vigo Consulting (IR and PR for Arecor) Melanie Toyne Sewell, Rozi Morris	+44 (0) 20 7390 0230 [email protected]

Sequel Med Tech LLC Gabby Fernandes, VP, Finance & Investor Relations	[email protected]

Notes to Editors

About Arecor

Arecor Therapeutics plc is a clinical stage biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases. The Company is applying its proprietary technology platform, Arestat®, to develop a portfolio of proprietary products, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. Its lead product is AT278, the only ultra-concentrated (500U/mL) ultra-rapid acting insulin. Arecor is also developing a novel oral delivery platform for peptides (e.g. GLP-1 receptor agonists) targeting the obesity and diabetes markets. The Company is listed on AIM (AIM: AREC) and is based in Cambridge, UK. For further details please see www.arecor.com.

Arecor® and Arestat® are registered trademarks of Arecor Limited.

About Sequel Med Tech

Headquartered in Manchester, New Hampshire, US, Sequel is developing the next generation of transformative drug-delivery advancements. Sequel's approach is to look at diabetes management holistically to advance systems that make living with diabetes simpler and easier for all. Sequel was co-founded by visionary Dean Kamen, serial entrepreneur Pablo Legorreta, seasoned medical device executive Bill Doyle and healthcare leader Alan Lotvin, MD. Sequel's focus is to bring the latest developments in science and technology to the marketplace, helping drive more accessible drug delivery. For more information, please visit www.sequelmedtech.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCSSMFDMEMSEIF